Clinical trial
A Phase 3, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT04944784 is registered in ClinicalTrials.gov with Cytokinetics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)
- Lead sponsor
- Cytokinetics
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- August 16, 2021
- Completion date
- July 18, 2023
- Enrollment
- 489 (actual)
- Sites
- 84
Conditions
As the registry lists them; a condition with its own page is linked.